Ex-Vivo Treg Modification for ALS
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
120
NCT07161999
Study of COYA 302 for the Treatment of ALS
Phase: Phase 2
Role: Lead Sponsor
Start: Oct 1, 2025
Completion: Jul 31, 2027
Loading map...